JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

ESPERION THERAPEUTICS INC

Gesloten

SectorGezondheidszorg

2.7 1.5

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.7

Max

2.75

Belangrijke statistieken

By Trading Economics

Inkomsten

28M

-13M

Verkoop

17M

82M

Winstmarge

-15.446

Werknemers

304

EBITDA

37M

16M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+155.35% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

358M

653M

Vorige openingsprijs

1.2

Vorige sluitingsprijs

2.7

Nieuwssentiment

By Acuity

50%

50%

147 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

ESPERION THERAPEUTICS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 okt 2025, 14:47 UTC

Belangrijke Marktbewegers

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

Peer Vergelijking

Prijswijziging

ESPERION THERAPEUTICS INC Prognose

Koersdoel

By TipRanks

155.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.92 USD  155.35%

Hoogste 16 USD

Laagste 1.6 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor ESPERION THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

4

Buy

0

Hold

1

Sell

Technische score

By Trading Central

0.85 / 1.05Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

147 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
help-icon Live chat